EydisBio Awarded $0.5 Million Grant to Advance TAK1 Inhibitor Program for Alzheimer's Disease

DURHAM, N.C., Oct. 23, 2024 /PRNewswire/ -- EydisBio, an innovative pharmaceutical company dedicated to developing novel treatments for various autoimmune and inflammatory diseases, is excited to announce that it has been awarded a $0.5 million Phase I Small Business Innovation Research...